Develops immune therapies for cancer.
Jun 2026Revenue $2.17M/yrExpenses $52.5M/yr
No trendCash runway ≈ 1 months from Jun 2026
Figures by year
When will Northwest Biotherapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $2.17M and expenses $52.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.38M | $61.3M | −$59.9M |
| Dec 2024 | $1.38M | $67.9M | −$66.5M |
| Dec 2023 | $1.93M | $57.4M | −$55.5M |
| Dec 2022 | $1.68M | $68.9M | −$67.2M |
| Dec 2021 | $1.00M | $53.7M | −$52.7M |
| Dec 2020 | $1.29M | $87.9M | −$86.6M |
| Dec 2019 | $2.41M | $30.4M | −$28.0M |
| Dec 2018 | $412K | $41.9M | −$41.5M |
| Dec 2017 | $336K | $55.0M | −$54.7M |
| Dec 2016 | $623K | $79.9M | −$79.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.